GLPG (Galapagos NV) Short-Term Debt to Capital

Corporate company logo of Galapagos NV (GLPG)

The historical price chart for Galapagos NV (GLPG) on GURU.Markets demonstrates financial resilience regarding the 0.00 metric, as colossal cash reserves offset research and development costs. The business relies on payments from industry behemoths and the development of new medications for cancer and autoimmune pathologies. Growth is driven by mergers with biotech projects and the launch of joint cell therapy programs.

Ratio of Short-Term Indebtedness to Capital: Galapagos Genomics (GLPG) for 07/04/2022 - 05/08/2026

Analytical breakdowns for Galapagos NV

- stock quotes and analyst forecast:
Stock Price Galapagos Genomics|GLPG - Fair Value Consensus
- business market valuation indicators:
Market Capitalization Galapagos N.V.|GLPG - Enterprise Value
- book capitalization information:
Net Assets per Single Share Galapagos|GLPG - Accounting Value of Company|Market Value to Book Value Ratio glpg.com|GLPG - Cumulative Company Assets
- company liabilities and liquidity data:
Total Debt to Capital Galapagos NV|GLPG - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Galapagos|GLPG - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Galapagos N.V.|GLPG - Long-Term Debt|Company Current Liabilities Galapagos|Quick Ratio glpg.com
- company profitability and valuation multiples indicators:
GLPG - Final Profit
Fundamental valuation:GLPG Galapagos Genomics
Brand item of Galapagos N.V.

It is critical for investors to assess the stability of Galapagos NV through the ratio of liabilities maturing within one year to equity, which determines the extent to which expansion depends on borrowed funds. By analyzing the volume of short-term loans relative to equity, one can confirm a low risk of liquidity gaps, as the company's multi-billion dollar cash reserves completely neutralize the pressure of current debts and cover R&D costs.

Competitors of Galapagos NV (GLPG)

Short-Term Debt to Capital HLN|KVUE (Kenvue Health) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital VRNA (Verona Pharma plc)|Short-Term Debt to Capital jyongbio.com MENS|LGND - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital AMRX (Amneal Pharmaceuticals, Inc.)|Perrigo Company (PRGO) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio Alvotech Biopharmaceuticals|LQDA (Liquidia Corporation) - Short-Term Debt to Capital|Short-Term Debt to Capital anipharmaceuticals.com|Short-Term Debt to Equity Ratio MNKD (MannKind)|AMPH (Amphastar Pharmaceuticals Inc) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Pacira PCRX|ARS Corp (SPRY) - Current Liabilities to Capital|TBPH: Short-Term Debt to Equity Ratio|aquestive.com - Short-Term Loans to Capital Ratio|SCPH: Short-Term Debt to Capital|Tectonic Therapeutic - Ratio of Short-Term Indebtedness to Capital|TNXP (Tonix Pharmaceuticals Inc.) - Short-Term Debt to Capital|Current Liabilities to Capital SXT China SXTC|Short-Term Debt to Equity Eupraxia Pharmaceuticals (EPRX)|BHST (bioharvest.com) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital EXOZ (eXoZymes)|Short-Term Indebtedness to Equity Oramed|Entera Bio Corp - Short-Term Debt to Capital|HYFT - Short-Term Debt to Capital|ABVC BioPharma (ABVC) - Short-Term Debt to Equity|CPIX (cumberlandpharma.com) - Short-Term Debt to Equity|QNTM (Quantum BioPharma) - Short-Term Debt to Capital|Short-Term Debt to Capital FibroGen Inc|Short-Term Debt to Equity Telomir Pharma (TELO)|RANI: Current Liabilities to Equity|Short-Term Debt to Capital SNYR (Synergy CHC)|Short-Term Debt to Capital Rallybio Corp RLYB|Lexaria - Short-Term Debt to Capital|Short-Term Indebtedness to Equity Pulmatrix Inc (PULM)|ftzy.com.cn (PTHL) - Short-Term Debt to Equity|Current Liabilities to Capital Aptorum Group (APM)|Short-Term Debt to Equity Lyra Therapeutics, Inc.|impactbiomedinc.com (IBO) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio TNFA (TNF Pharmaceuticals)|YCBD (cbdmd.com) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity PainReform Limited PRFX|CYTO: Short-Term Debt to Capital Ratio|LIPO: Short-Term Debt to Equity Ratio|OPTN: Short-Term Debt to Equity|PIRS: Short-Term Debt to Capital|Short-Term Indebtedness to Equity Procaps Group PROC|Short-Term Debt to Equity Petros|Short-Term Debt to Equity QLI|Short-Term Debt to Equity Acelyrin, Inc. (SLRN)|TFFP: Current Liabilities to Equity